NCT07425054 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07425054
Title	ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (CHART-AC)
Acronym	CHART-AC
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Jennifer Dorth
Indications	anal canal squamous cell carcinoma anal margin squamous cell carcinoma
Therapies	Fluorouracil + Mitomycin C Fluorouracil + Mitomycin C + Retifanlimab Capecitabine + Mitomycin C + Retifanlimab Capecitabine + Mitomycin C
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center	NOT_YET_RECRUITING	Cleveland	Ohio	44106	United States	Details
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center	RECRUITING	Cleveland	Ohio	44195	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07425054Clinical Trial Detail